AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. – 21. (Canceled)

22. (Currently Amended) ~~The~~ A liposome encapsulating a water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less, ~~according to claim 1,~~ which is manufactured by the following steps:

(a) dissolving a ~~phospholipid and a triglycerol~~ phospholipid, a triglycerol, and cholesterol in a water-immiscible organic solvent, and mixing the resulting solution with an aqueous solution of ~~a medicament,~~ the water-soluble substance,

(b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,

(c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and

(d) removing the organic solvent from the double emulsion.

23. (Previously Presented) The liposome according to claim 22, wherein the particle size of the W/O emulsion is 30 to 100 nm.

24. (Canceled)

25. (Withdrawn and Currently Amended) A method of producing a liposome, ~~the liposome of claim 1,~~ which comprises the following steps:

(a) dissolving a ~~phospholipid and a triglycerol~~ phospholipid, a triglycerol, and cholesterol in a water-immiscible organic solvent, and mixing the resulting solution with an aqueous solution of a ~~medicament,~~ water-soluble substance,

(b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,

(c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and

(d) removing the organic solvent from the double emulsion, thereby producing a liposome encapsulating the water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less.

26. (Withdrawn) The method according to claim 25, wherein the particle size of the W/O emulsion is 30 to 100 nm.

27. (Canceled)

28. (New) A liposome encapsulating a water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less and contains a triglycerol and cholesterol.

29. (New) The liposome according to claim 22, which has a particle size of 200 nm or less.

30. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.

31. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.

32. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound.

33. (New) The liposome according to claim 30, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.

34. (New) The liposome according to claim 30, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.

35. (New) The liposome according to claim 34, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.

36. (New) The liposome according to claim 22, wherein the triglycerol is triolein.

37. (New) The liposome according to claim 22, wherein the amount of triglycerol is 1 to 15 mol % based on the total lipids.

38. (New) The liposome according to claim 22, wherein a ligand and/or a water-soluble synthetic polymer is bound to a surface of the liposome.

39. (New) The liposome according to claim 22, wherein a ligand is bound to a surface of the liposome.

40. (New) The liposome according to claim 38, wherein the ligand has an affinity to a target cell or a target molecule.

41. (New) The liposome according to claim 38, wherein the ligand is an antibody or an antibody fragment.

42. (New) The liposome according to claim 38, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.

43. (New) The liposome according to claim 38, wherein the water-soluble synthetic polymer is polyalkylene glycol.

44. (New) The liposome according to claim 42, wherein the polyalkylene glycol is polyethylene glycol.

45. (New) The liposome according to claim 38, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

46. (New) A pharmaceutical composition containing the liposome according to claim 22.

47. (New) The liposome according to claim 28, which has a particle size of 200 nm or less.

48. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.

49. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.

50. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound.

51. (New) The liposome according to claim 48, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.

52. (New) The liposome according to claim 48, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.

53. (New) The liposome according to claim 52, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.

54. (New) The liposome according to claim 28, wherein the triglycerol is triolein.

55. (New) The liposome according to claim 28, wherein the amount of triglycerol is 1 to 15 mol % based on the total lipids.

56. (New) The liposome according to claim 28, wherein a ligand and/or a water-soluble synthetic polymer is bound to surface of the liposome.

57. (New) The liposome according to claim 28, wherein a ligand is bound to surface of the liposome.

58. (New) The liposome according to claim 56, wherein the ligand has an affinity to a target cell or a target molecule.

59. (New) The liposome according to claim 56, wherein the ligand is an antibody or an antibody fragment.

60. (New) The liposome according to claim 56, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.

61. (New) The liposome according to claim 56, wherein the water-soluble synthetic polymer is polyalkylene glycol.

62. (New) The liposome according to claim 60, wherein the polyalkylene glycol is polyethylene glycol.

63. (New) The liposome according to claim 56, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

64. (New) A pharmaceutical composition containing the liposome according to claim 28.